Marble Wealth LLC Purchases Shares of 3,341 Astrazeneca Plc $AZN

Marble Wealth LLC acquired a new position in shares of Astrazeneca Plc (NYSE:AZN) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 3,341 shares of the company’s stock, valued at approximately $586,000.

Other institutional investors have also recently made changes to their positions in the company. Bank of Montreal Can increased its holdings in Astrazeneca by 344.6% in the third quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock valued at $266,841,000 after buying an additional 2,695,793 shares in the last quarter. Holocene Advisors LP raised its position in shares of Astrazeneca by 41.8% in the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock worth $470,232,000 after acquiring an additional 1,807,565 shares during the period. Bank Julius Baer & Co. Ltd Zurich boosted its stake in shares of Astrazeneca by 11,190.9% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock worth $317,107,000 after acquiring an additional 1,790,874 shares in the last quarter. Raymond James Financial Inc. grew its position in shares of Astrazeneca by 64.8% during the 2nd quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock valued at $264,373,000 after acquiring an additional 1,487,662 shares during the period. Finally, Bank of America Corp DE grew its position in shares of Astrazeneca by 4.7% during the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after acquiring an additional 1,461,786 shares during the period. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on AZN shares. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research note on Thursday, May 21st. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Astrazeneca presently has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Trading Down 0.7%

Shares of AZN opened at $176.28 on Thursday. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71. The stock has a market cap of $273.39 billion, a PE ratio of 26.47, a price-to-earnings-growth ratio of 1.41 and a beta of 0.25. The firm’s fifty day moving average is $190.88 and its two-hundred day moving average is $184.54. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last issued its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Research analysts forecast that Astrazeneca Plc will post 10.26 earnings per share for the current fiscal year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.